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ABSTRACT
Introduction
Maximal androgen blockade (MAB) versus castration
alone in patients with metastatic prostate cancer has
been extensively evaluated in randomized trials. The
inconsistent results have led to the publication of
multiple meta-analyses. The present review exam-
ines the evidence from meta-analytic reports to de-
termine whether MAB using agents such as flutamide,
nilutamide, and cyproterone acetate (CPA) is associ-
ated with a survival advantage.
Methods
We conducted a systematic review of the literature
(MEDLINE, EMBASE, and the Cochrane Library through
July 2004; CANCERLIT through October 2002) for meta-
analyses that compared MAB with castration alone in
previously untreated men with metastatic prostate
cancer (D1 or D2, N+/M0 or M1). Two reviewers
selected papers for eligibility; disagreement was re-
solved by all the authors through consensus.
Results
The literature search identified six meta-analyses that
met the eligibility criteria of the review. Two of those
reports were based on individual patient data (IPD),
and four were based on data from the published lit-
erature. All six meta-analyses pooled data on overall
survival.
The best evidence came from the largest meta-
analysis, conducted by the Prostate Cancer Trialists
Collaborative Group and based on IPD (8725 patients)
from 27 trials. That analysis detected no difference
in overall survival between MAB and castration alone
at 2 or 5 years. However, a subgroup analysis showed
that MAB with nonsteroidal anti-androgens (NSAAs) was
associated with a statistically significant improvement
in 5-year survival over castration alone (27.6% vs.
24.7%; p = 0.005). The combination of MAB with CPA,
a steroidal anti-androgen, was associated with a sta-
tistically significant increased risk of death (15.4%
vs. 18.1%; p = 0.04). Compared with castration alone,
MAB was associated with more side effects (that is,
gastrointestinal, endocrine function) and reduced
quality of life in domains related to treatment symp-
toms and emotional functioning.
Conclusions
The small survival benefit conferred by MAB with NSAA
is of questionable clinical significance given the
added toxicity and concomitant decline in quality of
life observed in patients treated with MAB. Therefore,
combined treatment with flutamide or nilutamide
should not be routinely offered to patients with meta-
static prostate cancer beyond the purpose of block-
ing testosterone flare. Monotherapy, consisting of
orchiectomy or the administration of a luteinizing
hormone–releasing hormone agonist is recommended
as standard treatment.
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1. INTRODUCTION
Prostate cancer is currently the most prevalent form
of male cancer in Canada 1. At diagnosis, 20%–30%
of patients will present with advanced or metastatic
disease. Of those men, approximately 25% will die
from their disease within 2 years 2. Therapeutic in-
terventions seek not only to increase survival in
those patients, but also to improve quality of life
(QOL) 3.
The mainstay of treatment for advanced or meta-
static prostate cancer is to inhibit the biosynthesis of
androgens, the hormones responsible for prostate
cancer cell growth. Androgen suppression can be
achieved through surgical (bilateral orchiectomy) or
medical castration. Medical castration involves the
long-term use of luteinizing hormone–releasing hor-
mone (LHRH) agonists. The two methods of castra-
tion appear equally effective in removing testicular
androgens 4.
The testes are the major locale for testosterone
production; however, the adrenal glands also produce
a small but measurable quantity of androgens. It has
been hypothesized that removing all circulating an-
drogens—by blocking adrenal androgens in addition
to inhibiting testicular androgen production—might
be beneficial to patients. Combination treatment, in
the form of surgical or medical castration plus ad-
ministration of an anti-androgen [for example,
flutamide, nilutamide, or cyproterone acetate (CPA)]
is called “maximal androgen blockade” (MAB).
The use of MAB was first introduced in the early
1980s 5. Since then, a large number of randomized
controlled trials have been conducted to evaluate the
efficacy of MAB as compared with castration alone.
The trials yielded inconsistent results. Most failed to
provide convincing evidence of improved survival
with  MAB; however, a few of the larger trials detected
survival benefits with combined treatment 6–8. Low
statistical power, study immaturity, compliance to
treatment, and imbalances in prognostic indicators
between study arms of individual trials were impli-
cated as potential sources of discrepancy 9–13.
Recent attempts to determine the treatment effi-
cacy of MAB have involved meta-analyses of the tri-
als 14. To determine whether MAB is associated with a
survival advantage, the present review systematically
examines the results of the meta-analyses comparing
MAB with castration alone in patients with metastatic
prostate cancer.
2. MATERIALS AND METHODS
The present systematic review was originally com-
pleted in the context of developing a clinical prac-
tice guideline for Cancer Care Ontario’s Program in
Evidence-Based Care (PEBC), using the methodology
of the Practice Guidelines Development Cycle 15. The
literature was searched by one member of PEBC’s
Genitourinary Cancer Disease Site Group. Evidence
was reviewed and selected by two members, and dis-
agreements pertaining to eligibility were handled
through consensus involving the five members of
the writing group. Two reviewers assessed eligible
reports for important aspects of methodologic qual-
ity as expressed in the Quorom statement 16
(Appendix A).
2.1 Literature Search Strategy
We conducted a systematic search of MEDLINE (1980
through July 2004), EMBASE (1980 through 2004
wk 27),  CANCERLIT (1980 through October 2002), and
the Cochrane Library (2004, Issue 2) databases. In
each database, subject headings were combined with
disease-specific, treatment-specific, and design-spe-
cific search terms (Appendix B). The reference lists
of all articles found, including reviews and articles
held in personal files, were reviewed for additional
citations. The search was restricted to reports pub-
lished in the English language.
2.2 Eligibility Criteria
Published reports or abstracts of meta-analyses com-
paring MAB (orchiectomy or LHRH agonist plus admin-
istration of an anti-androgen) with castration alone
(orchiectomy or LHRH agonist) in previously untreated
men with metastatic prostate cancer (D1 or D2, N+/
M0 or M1) were eligible for inclusion. Papers were
required to report overall mortality or disease pro-
gression-related outcomes, or both. Adverse effects
and QOL were also outcomes of interest.
3. RESULTS
3.1 Literature Search Results
We identified eleven reports representing seven
unique meta-analyses 17–27. One meta-analysis was
excluded based on language 27, leaving six analyses
eligible for inclusion in the review 18,20,22–24,26
(Table I). Two meta-analyses pooled individual pa-
tient data (IPD) 18,26, and four pooled summary data
from published trial reports (literature-based) 20,22–24.
3.1.2 IPD Meta-analyses
Bertagna et al. 25 published the first IPD meta-analy-
sis in 1994. That analysis was limited to seven double-
blind, placebo-controlled trials of MAB with nilutamide
(1056 patients). An update published in abstract form
by Debruyne et al. 26 provided extended follow-up
data on survival and disease progression.
In 1995, the Prostate Cancer Trialists’ Collabo-
rative Group (PCTCG) published an IPD meta-analysis
that included 22 MAB trials (5710 patients) 17. All ran-
domized trials that compared castration alone to MAB,
both published and unpublished, were sought forCURRENT ONCOLOGY—VOLUME 13, NUMBER 3
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TABLE I Meta-analyses identified by the literature search—descriptions
Meta-analysis Trials included in meta-analysis: MAB with
Flutamide Nilutamide CPA
Individual patient data (IPD) meta-analyses
PCTCG 2000 18 Bono (ILG), 1998 28 Dijkman (IASG), 1997 8 De Voogt (EORTC), 1998 44
31 RCTs included in review Denis (EORTC), 1998 7 Bertagna, 1994 25 Theiss, 1996 45
27 RCTs provided IPD for meta-analysis Eisenberger (NCI/SWOG), 1998 29 Béland (CASG), 1990 38 Thorpe, 1996 46
12 flutamide trials Ferrari (Italy), 1996 30 Crawford, 1990 39 Robinson (EORTC), 1995 47
8 nilutamide trials Zalcberg (Australia), 1996 31 Namer, 1990 40 Jorgensen (SPCG), 1993 48
7 CPA trials Boccardo (PONCAP), 1993 32 Knonagel, 1989 41 DiSilverio (Italy), 1990 49
88% of patients staged “metastatic”; Fourcade (France), 1993 33 Brisset, 1987 42
12% staged “locally advanced” Iversen (DAPROCA), 1993 34 Navratil, 1987 43
Tyrrell (IPCSG), 1993 35
Crawford (NCI), 1989 6
Schulze (WPSG), 1988 36
Delaere, 1987 37
Bertagna 1994 25, Debruyne 1996 26 None Bertagna, 1994 25 None
Included 7 double-blind RCTs Janknegt (IASG), 1993 50
7 nilutamide trials Brisset, 1990 51
% of patients staged D not reported Namer, 1990 40
Knonagel, 1989 41
Béland (CASG), 1988 52
Literature-based meta-analyses
Schmitt 2003 22 Bono (ILG), 1998 28 Dijkman (IASG), 1997 8 None
20 RCTs included in review Eisenberger (NCI/SWOG/INT- Béland (CASG), 1990 38
14 RCTs provided data for meta-analysis a 1015), 1998 29 Crawford, 1990 39
9 flutamide trials Zalcberg (Australia), 1996 31 Namer (France), 1990 40
5 nilutamide trials Boccardo (PONCAP), 1993 32 Brisset, 1987 42
96% of patients were stage D2 or M1 Denis (EORTC), 1993 53 Tyrrell (IPCSG), 1991 54
Fourcade (France), 1990 55
Iversen (DAPROCA), 1990 56
Crawford (NCI), 1989 6
Aronson 1999 20 Same as above Same as above Robinson (EORTC), 1995 47
27 RCTs included in review Jorgensen (SPCG), 1993 48
20 RCTs provided data for meta-analysis DeVoogt (EORTC), 1990 57
9 flutamide trials DiSilverio (Italy), 1990 49
5 nilutamide trials Williams (U.K.), 1990 58
6 CPA trials Klosterhalfen, 1987 59
93% of patients were stage D2
Bennet 1999 23 Eisenberger (NCI/SWOG), 1998 29 None None
9 RCTs included in review Zalcberg (Australia), 1996 31
9 RCTs provided data for meta-analysis Boccardo (PONCAP), 1993 32
9 flutamide trials Denis (EORTC), 1993 4
98% of patients were stage D Fourcade (France), 1993 33
Tyrrell (IPCSG), 1991 54
Iversen (DAPROCA), 1990 56
Crawford (NCI), 1989 6
Schulze (WPSG), 1988 36
Caubet 1997 24 Boccardo (PONCAP), 1993 32 Janknegt (IASG), 1993 50 None
13 RCTs included in review Denis (EORTC), 1993 4 Béland (CASG), 1991 38
9 RCTs provided data for meta-analysis Iversen (DAPROCA), 1993 34 Navratil, 1987 43
6 flutamide trials Tyrrell (IPCSG), 1993 35
3 nilutamide trials Crawford (NCI), 1989 6
57%–100% of patients staged D2 Schulze (WPSG), 1988 36
a The 14 trials listed in Table I contributed to the pooled analysis of 2-year survival data. Thirteen trials 6,8,28,29,31,32,34,38,40,42,53–55 and seven
trials 6,8,28,29,34,53,54 contributed to the pooled analysis of 1-year and 5-year survival data, respectively.
MAB = maximal androgen blockade; CPA = cyproterone acetate; PCTCG = Prostate Cancer Trialists’ Collaborative Group; RCTs = randomized
controlled trials; ILG = Italian Leuprorelin Group; EORTC = European Organization for Research and Treatment of Cancer; NCI = National
Cancer Institute; SWOG = Southwest Oncology Group; PONCAP = Italian Prostatic Cancer Project; DAPROCA = Danish Prostatic Cancer Group;
IPCSG = International Prostate Cancer Study Group;  WPSG = Westfälische Prostatakarzinom Study Group; IASG = International Anandron
Study Group; CASG = Canadian Anandron Study Group; SPCG = Scandinavian Prostatic Cancer Group.84
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inclusion. The main limitations of the report include
the absence of explicitly defined eligibility criteria, a
description of the methods used to identify and se-
lect trials, an appraisal of trial quality and its influ-
ence on the pooled results, and an indication of
whether subgroup analyses were planned a priori
(Appendix A). The report is also limited by the fact
that overall mortality was the only outcome analyzed;
other important endpoints, including toxicity and QOL
were not examined. The meta-analysis was updated
in 2000 18 to include a total of twenty-seven trials:
twelve used flutamide, eight used nilutamide, and
seven used CPA as the anti-androgen. In combining
data on 8725 patients, this updated report represents
the most extensive quantitative analysis of MAB trials
conducted to date.
3.1.3 Literature-based Meta-analyses
The number of trials included in the four literature-
based meta-analyses ranged from nine (1978 patients)
to twenty (6745 patients; Table I). The largest analy-
sis was conducted for the Agency for Health Care
Policy Research (AHCPR) by Aronson et al. 20. The
review was well conducted, with trials systematically
identified through a prospectively designed protocol
that specified the objectives, literature search strat-
egy, eligibility criteria, method of assessing trial qual-
ity, and subgroup and sensitivity analyses, including
an assessment of publication bias (Appendix A).
Twenty-seven MAB trials were identified, including
twelve using flutamide, eight using nilutamide, and
seven using CPA. Overall mortality was the only out-
come for which data were statistically pooled, but
data on disease progression, QOL, and adverse effects
were also summarized.
The three other literature-based meta-analyses
were restricted in scope, analyzing trials that com-
pared castration with MAB using nonsteroidal anti-
androgens (NSAA) 22–24. The largest of those analyses,
carried out by Schmitt et al. 22 for the Cochrane Pro-
static Diseases and Urologic Cancers Group, included
twenty trials and pooled data on overall mortality,
progression-free survival (PFS), and cancer-specific
survival. Bennett et al. 23 and Caubet et al. 24 both
included nine trials and pooled data on overall mor-
tality 23,24 and PFS 24.
3.2 Outcomes
3.2.1 Overall Survival
IPD Meta-analyses Results from the original PCTCG
overview showed a small survival benefit with MAB
that was not statistically significant (5-year survival:
22.8% vs. 26.2%; p > 0.1) 17. In the updated meta-
analysis (2000), the PCTCG reported a nonsignificant
overall hazard ratio (HR) of 0.96 [95% confidence
interval (CI): 0.91–1.01; p = 0.11], where ratios less
than 1 favoured MAB 18 (Table II). Further analyses at
different follow-up periods also showed no differ-
ence in mortality and suggested an absolute 5-year
survival difference of approximately 2% in favour
of MAB. Subgroup analyses were performed by
method of androgen suppression (orchiectomy vs.
LHRH agonist), type of anti-androgen, patient age,
stage of disease (metastases vs. no metastases), and
non–prostate cancer mortality. With the exception
of type of anti-androgen, no significant differences
in treatment effect were observed within any of those
subgroups. A small and statistically significant sur-
vival benefit was detected for MAB with flutamide
(HR = 0.92; 95% CI: 0.86–0.98; p = 0.02), and a simi-
lar but nonsignificant result was observed for
nilutamide. MAB with CPA was associated with a sig-
nificantly worse survival outcome than castration
alone (HR = 1.13; 95% CI: 1.01–1.25; p = 0.04). Treat-
ment with MAB containing either of the NSAAs in-
creased 5-year survival over castration alone by 3%
(27.6% vs. 24.7%, p = 0.005).
Debruyne et al. 26 reported a reduction in the odds
of death in patients treated with nilutamide-contain-
ing MAB; MAB was associated with a 16% reduction in
mortality as compared with castration alone [odds
ratio (OR) = 0.84; 95% CI: 0.71–0.99; p = 0.038].
Literature-based Meta-analyses Table III summarizes
the results for overall mortality from the four litera-
ture-based meta-analyses. Aronson et al. 20 detected
no significant difference in overall mortality at
2 years, although at 5 years, overall mortality was
significantly improved with MAB (HR = 0.87; 95% CI:
0.81–0.94). However, the 5-year estimate was based
on half the trials (10 trials, 66% of patients) that con-
tributed to the 2-year estimate. No differences in treat-
ment effect were detected in any of the subgroup
analyses performed (method of androgen suppres-
sion, stage of disease, type of anti-androgen, or trial
quality).
Schmitt et al. 22 reported no difference in mor-
tality at 1 or 2 years between NSAA MAB and castra-
tion-only arms, but 5-year mortality was better with
MAB (OR = 1.29; 95% CI: 1.11–1.50; p = 0.0009). The
two other literature-based reports examining NSAA
MAB detected significant reductions in the risk for
mortality with MAB that ranged between 10% and
22% 23,24.
3.2.2 Disease Progression
Pooled analyses of disease progression data were
available from three of the six meta-analyses 22,24,26;
however, those analyses are limited by the inclusion
of a small proportion of MAB trials. Each of those re-
ports combined data from trials of MAB using NSAA.
Debruyne et al. 26 reported that, among seven trials,
the odds of progression were reduced by 17% by MAB
with nilutamide (OR = 0.83; 95% CI: 0.70–0.98; p =
0.031). Schmitt et al. 22 pooled published PFS data at
1 (seven trials), 2 (five trials), and 5 years (two tri-
als); the odds of progression were significantlyCURRENT ONCOLOGY—VOLUME 13, NUMBER 3
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reduced with MAB at 1 year (OR = 1.38; 95% CI: 1.15–
1.67; p = 0.0006), but not at 2 or 5 years. Caubet et
al. 24 reported a 23%–26% reduction in the risk for
progression with MAB depending on the type of meta-
analytic method used [relative risk (RR) = 0.74, p <
0.001 among seven trials; RR = 0.77, p < 0.001 among
seven trials].
A more representative presentation of disease
progression data was provided by Aronson et al. 20.
They summarized twenty-three trials 6,8,29,30,32,36,38–
40,42,43,46–49,53–58,60 reporting those data. Nineteen of
the trials reported no significant difference between
MAB and castration alone on those measures 29,30,
32,36,38–40,42,43,46–49,54–58,60. Among six trials reporting
TABLE II Results (mortality for maximal androgen blockade vs. castration alone a) from the 2000 Prostate Cancer Trialists’ Collaborative
Group individual patient data meta-analysis
Estimated HR (95% CI), p value
Overall mortality (n=8725) 0.96 (0.91–1.01), 0.11
By years since randomization:
Year 0 1.01 (0.91–1.11), NR
Years 1–2 0.93 (0.85–1.01), NR
Years 3–4 0.97 (0.85–1.09), NR
Year 5 onward 0.94 (0.76–1.12), NR
5-Year survival estimates:
25.4% vs. 23.6%, p>0.1
Subgroup analyses
Age
<65 (n=1641) 0.90 (0.78–1.02), NR
65–74 (n=3094) 0.96 (0.88–1.04), NR
³75 (n=2487) 0.95 (0.85–1.05), NR
Stage of disease
Definite metastases (n=7190) 0.95 (0.89–1.01), NR
No metastases (n=1025) 1.06 (0.86–1.30), NR
Non-prostate cancer mortality (n=4876) 1.04 (0.88–1.20), 0.7
Type of anti-androgen
Flutamide (n=4803) 0.92 (0.86–0.98), 0.02
Nilutamide (n=1751) 0.92 (0.80–1.04), >0.1
CPA (n=1661) 1.13 (1.01–1.25), 0.04
Class of anti-androgen 5-Year survival estimates:
Non-steroidal (flutamide + nilutamide; n=6500) 27.6% vs. 24.7%, p=0.005
Steroidal (CPA; n=1800) 15.4% vs. 18.1%, p=0.04
HR = hazard ratio; CI = confidence interval; NR = not reported; CPA = cyproterone acetate.
TABLE III Results from literature-based meta-analyses of maximal androgen blockade (MAB)
Meta-analysis Mortality results [estimated HR (95% CI), p value]
MAB with any anti-androgen vs. castration alone a
Aronson 1999 20 2-year 5-year
(20 trials, 6745 patients) (10 trials, 4443 patients)
0.97 (0.87–1.09), NR 0.87 (0.81–0.94), NR
MAB with non-steroidal anti-androgens vs. castration alone a
Schmitt 2003 22 1-year 2-year 5-year
(13 trials, 4970 patients) (14 trials, 5286 patients) (7 trials, 3550 patients)
1.03 b (0.85–1.25), 0.7 1.14 b (1.00–1.31), 0.06 1.29 b (1.11–1.50), 0.0009
Bennet 1999 23 Overall (9 trials, 4128 patients) 0.90 (0.79–1.00), NR
Caubet 1997 24 Overall: Method 1 c (7 trials, 1978 patients) 0.78 (0.67–0.90), <0.001
Overall: Method 2 c (7 trials, 2592 patients) 0.84 (0.76–0.93), <0.001
a Unless otherwise specified, summary statistic values less than 1 favour MAB and values greater than 1 favour castration alone.
b Odds ratio. A ratio greater than 1 favours MAB; a ratio less than 1 favours castration alone.
c Method 1: Hazard ratios were derived by reconstructing annual life tables from survival curves and fitting discrete proportional hazard
models. Method 2: Hazard ratios were derived from reported p values and numbers of deaths.
HR = hazard ratio; CI = confidence interval; NR = not reported.86
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PFS 6,8,29,32,36,47, two reported a statistically significant
longer progression-free interval with MAB 6,8. Both of
those trials used an NSAA in the MAB arm. One trial
compared orchiectomy plus placebo with orchiec-
tomy plus nilutamide (median PFS: 15 months vs.
21 months; p = 0.002) 8, and the other compared
leuprolide plus placebo with leuprolide plus flutamide
(median PFS: 14 months vs. 17 months; p = 0.039) 6.
Of the seventeen trials that reported on time-to-dis-
ease progression (TTP) 4,30,38–40,42,43,46,48,49, 54–56,58,60,
one trial comparing orchiectomy with goserelin plus
flutamide detected a significantly longer TTP interval
with MAB (median TTP: 18 months vs. 12 months; p =
0.002) 4.
3.2.3 QOL and Adverse Effects
Aronson et al. 20 wrote the only report that reviewed
QOL and adverse effects. Among the 27 randomized
controlled trials that those authors reviewed, only one
formally assessed QOL. The authors summarized two
reports 61,62 of the large National Cancer Institute (NCI)
INT-0105 Southwest Oncology Group/Eastern Coop-
erative Oncology Group trial 29, which compared or-
chiectomy plus flutamide with orchiectomy plus
placebo. Measures of QOL included three treatment-
related symptoms (diarrhea, gas pain, and body
image), physical functioning, and emotional function-
ing; all were assessed at 1, 3, and 6 months after the
start of treatment. Patients treated with MAB experi-
enced significantly more diarrhea at 3 months (p <
0.001) and worse emotional functioning at 3 and
6 months (p < 0.003) than did patients treated with
castration alone. Nonsignificant trends toward poor
scores on measures of physical functioning, fatigue,
abdominal gas, overall pain, and body image were
also observed with MAB.
Major limitations were present in the reporting
of adverse effects in the MAB trials. Because of those
limitations, data on adverse effects were supple-
mented with similar data from package inserts that
accompany therapeutic agents marketed in the United
States and from phase II studies. Tables IV and V sum-
marize the adverse effects data contained in the
Aronson et al. report 20. Compared with castration
alone, treatment with MAB that included NSAA appeared
to produce more gastrointestinal-related problems and
more frequent withdrawal from treatment. When MAB
contained  CPA, treatment was associated with more
complications related to endocrine function, but a
withdrawal pattern similar to that in patients receiv-
ing monotherapy was demonstrated.
4. DISCUSSION
Six meta-analyses form the evidence base of the
present review 17,18,20,22–25. Evidence from those
analyses suggests that patient outcomes depend on
the type of anti-androgen used with MAB. The PCTCG
meta-analysis 18 showed that MAB was not associated
with a statistically significant improvement in over-
all survival. However, when outcomes were analyzed
by type of anti-androgen, varying treatment effica-
cies among the agents were evident. Small but statis-
tically significant survival benefits in the range of
3% at 5 years were detected among trials that used
MAB with an NSAA (as compared with castration alone).
Compared with castration alone, MAB with CPA (a ste-
roidal anti-androgen) was associated with an approxi-
mate 3% increased risk of death.
Variability in the magnitude of outcome among
meta-analyses may arise from a number of factors,
including the number and size of the trials contribut-
ing to the pooled estimate, the type of anti-andro-
gens being evaluated, and the use of published
summary data or IPD for the analyses. The four litera-
ture-based meta-analyses 20,22–24 included fewer tri-
als (and fewer patients) than did the PCTCG
meta-analysis, but the resulting pooled estimates were
of greater magnitude (in favour of MAB) than were
those generated using IPD 18. In meta-analyses based
on published data, publication bias is more likely to
exaggerate treatment effects 63. Only one of the four
literature-based meta-analyses assessed the influence
of publication status on the overall pooled result 20.
With IPD, many of the problems associated with pub-
lished data that introduce bias are eliminated by the
ability to incorporate all trial data (published and
unpublished), to check the integrity of patient ran-
domization, and to perform proper time-to-event
analyses (as compared with fixed time point) by in-
tent-to-treat 64,65. Further, because of greater patient
numbers, IPD often provides greater statistical power
to properly perform subgroup analyses 65. The
methodologic weaknesses of the PCTCG have been
identified, but the advantages of using IPD currently
make the PCTCG meta-analysis the most reliable evi-
dence comparing MAB with castration alone.
To decide whether MAB should be the preferred
treatment for patients, the small survival benefit and
the additional adverse effects of combined treatment
must be balanced. The clinical significance of a sta-
tistically significant 3% improvement in survival
with NSAA MAB is questionable, especially when the
toxicity of MAB is considered. Data on adverse ef-
fects and QOL are limited, but they suggest increased
toxicity and a concomitant decline in QOL in MAB-
treated patients. In addition, data on disease progres-
sion provide further evidence that MAB does not
provide superior treatment efficacy over castration
alone 20.
Based on the evidence reviewed, MAB should not
be routinely offered to patients with metastatic pros-
tate cancer. Monotherapy, consisting of orchiectomy
or the administration of an LHRH agonist, should be
recommended as standard treatment.
It is important to distinguish between MAB as long-
term treatment and short-term use of MAB in the pre-
vention of testosterone flare. In patients treated withCURRENT ONCOLOGY—VOLUME 13, NUMBER 3
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medical castration, initial treatment with an LHRH ago-
nist is accompanied by a surge in serum testosterone
during the first week or weeks of therapy, followed
by a decline. That surge may exacerbate existing
metastatic disease 66,67,68, therefore short-term use of
an anti-androgen is indicated to prevent or block the
flare phenomenon 68. Administration of an anti-an-
drogen is reasonable for a period of 2–4 weeks when
treatment with an LHRH agonist is initiated.
Because of the small survival improvement ob-
served with MAB, some clinicians may still choose MAB
over monotherapy for individual patients. If MAB is
administered with this intent, MAB containing a NSAA
is suggested. Given its higher mortality, MAB with CPA
should be avoided as compared with castration alone 18.
The present review did not identify any meta-
analyses that included trials evaluating MAB with the
newer anti-androgen bicalutamide. Bicalutamide-
TABLE IV Adverse effects by category, combined results
Adverse effect Castration only MAB: MAB: Any MAB
Castration + NSAA Castration + CPA
Patients Studies Patients Studies Patients Studies Patients Studies
[n (%)] (n)[ n (%)] (n)[ n (%)] (n)[ n (%)] (n)
Cardiovascular
Cardiovascular, not specified 570 (4) 4 387 (4.9) 3 175 (1.7) 1 562 (3.9) 4
Edema 569 (3.2) 3 293 (2) 1 277 (6.5) 2 570 (4.2) 3
Endocrine
Hot flashes 2594 (40.1) 16 2789 (40) 12 488 (52.7) 4 3277 (41.9) 16
Gynecomastia 1441 (9.4) 10 1987 (7) 9 257 (17.5) 2 2244 (8.2) 11
Breast tenderness or pain 649 (7.7) 5 1206 (5.1) 5 257 (6.6) 2 1463 (5.4) 7
Impotence 515 (71.1) 5 362 (66) 4 156 (82.1) 1 518 (70.8) 5
Decreased libido 519 (70.1) 5 367 (65.4) 4 156 (78.8) 1 523 (69.4) 5
Gastrointestinal (GI)
GI, not specified 959 (2.3) 7 768 (10.3) 6 175 (0.6) 1 943 (8.5) 7
Nausea or vomiting 1872 (3.2–7.1) 8 1851 (5.6–9.2) 8 0 (0) 0 1851 (5.6–9.2) 8
Diarrhea 1464 (2.2) 6 1458 (8.2) 6 0 (0) 0 1458 (8.2) 6
GI pain 124 (1.6) 2 122 (7.4) 2 0 (0) 0 122 (7.4) 2
Hepatic
Hepatic, not specified 1197 (1.3) 4 2004 (5) 6 0 (0) 0
Increased liver enzymes 483 (2.7) 3 474 (6.8) 3 0 (0) 0 NR
Ophthalmologic Orchiectomy Orchiectomy + nilutamide
Ophthalmologic, not specified 407 (5.4) 3 396 (29) 3 NR NR
MAB = maximal androgen blockade; NSAA = nonsteroidal anti-androgen; CPA = cyproterone acetate; NR = not reported. Adapted, with permis-
sion, from Aronson et al. 20, Appendix II, Tables II-6 to II-10.
TABLE V Adverse effects leading to withdrawal from treatment, combined results
Treatment Studies (n) Treatment group (n) Withdrawals from treatment [n (%)]
Leuprolide (1 daily) 1 268 0 (0)
Goserelin (3.6, 1-month) 11 1679 33 (2)
Goserelin (10.8, 3-month) 2 77 1 (1.3)
Buserelin (0.4) 1 72 3 (4.2)
Orchiectomy + nilutamide (150) 2 271 38 (14)
Orchiectomy + nilutamide (300) 3 209 24 (11.5)
Orchiectomy + CPA (150) 1 102 3 (2.9)
Orchiectomy + CPA (300) 1 20 2 (10)
Orchiectomy or LHRH agonist or both 28 4275 82 (1.9)
Goserelin (3.6, 1-month) + flutamide (750) 5 846 94 (11.1)
Orchiectomy or LHRH agonist + flutamide (750) or both 9 2804 233 (8.3)
Orchiectomy or LHRH agonist + bicalutamide (50) or both 1 401 41 (10.2)
Orchiectomy or LHRH agonist + nilutamide (150 or 300) or both 5 480 62 (12.9)
Orchiectomy or LHRH agonist + CPA (150 or 300) or both 2 122 5 (4.1)
CPA = cyproterone acetate; LHRH = luteinizing hormone–releasing hormone. From Aronson et al. 20, Appendix II, Table II-11. Used with
permission.88
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based MAB has been compared in a randomized trial
only with combination flutamide 69. A castration-only
control arm was deemed unethical at the time the
bicalutamide trial was designed because MAB was
considered standard care (over monotherapy). The
trial compared bicalutamide plus an LHRH agonist with
flutamide plus an LHRH agonist and detected a sur-
vival improvement with bicalutamide that was not
statistically significant (median survival: 180 weeks
vs. 148 weeks; HR = 0.87; 95% CI: 0.72–1.05; p =
0.15) 69. With the exception of a higher incidence of
hematuria, bicalutamide appeared less toxic than
flutamide. Klotz et al. 70 recently re-analyzed the data
from the bicalutamide trial 69 and the PCTCG meta-
analysis (subgroup of trials comparing MAB with
flutamide versus castration alone) 18 to calculate an
estimate of the likely benefit of MAB with bicalutamide
relative to castration alone. They reported an esti-
mated HR of 0.80 (95% CI: 0.66–0.98) for bicaluta-
mide-based MAB versus castration alone, which
equates to a 20% relative reduction in the risk of death
with bicalutamide. On the basis of those data, use of
bicalutamide in patients who are offered MAB would
also be reasonable. A randomized trial comparing MAB
with bicalutamide to castration alone is ongoing, but
that trial is assessing bicalutamide at a dose of
80 mg 71. Before beginning MAB, selected patients
should be advised of the magnitude of the survival
benefit and on possible adverse effects and their po-
tential impact on QOL.
Progressive prostate cancer is usually detected
through a rise in prostate-specific antigen (PSA),
which usually predates clinical or radiologic evi-
dence of metastases. Most patients included in MAB
trials had documented metastases (stage D2), and
whether results from those trials are generalizable
to patients with a rising PSA without evidence of
metastatic disease is unknown. Only a handful of
trials have analyzed outcomes by extent of meta-
static involvement 4,6,11,29,34. Most of those have not
shown a benefit of MAB in patients with minimal
disease, although the subgroup analyses included
small numbers of patients. Only 12% of patients (ap-
proximately 1000) in the PCTCG meta-analysis 18 had
documented non-metastatic prostate cancer. An
analysis of those patients showed slightly worse
survival with MAB, although the difference did not
reach statistical significance. Prospective random-
ized trials to investigate the efficacy of MAB in that
subgroup of patients are warranted.
5. CONCLUSIONS
The small survival benefit conferred by MAB with NSAA
is of questionable clinical significance given the
added toxicity and concomitant decline in QOL ob-
served in patients treated with MAB. Therefore, com-
bined treatment with flutamide or nilutamide should
not be routinely offered to patients with metastatic
prostate cancer (beyond the purpose of blocking tes-
tosterone flare). Monotherapy consisting of orchiec-
tomy or the administration of a LHRH agonist is
recommended as standard treatment.
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APPENDIX A Meta-analysis quality, as evaluated using the quality of reporting of meta-analyses (Quorom) statement; closed circles denote
fully described items, open circles denote partially described items, and dashes denote items not described
Quorom checklist item Meta-analyses
IPD Literature-based
PCTCG 2000 18, Bertagna 1994 25, Schmitt Aronson Bennett Caubet
PCTCG 1995 17 Debruyne 1996 26 2003 22 1999 20 1999 23 1997  24
INTRODUCTION
Clinical problem — — ··· —
Biologic rationale for treatment · · ····
Rationale for review · · ····
METHODS
Searching
Information sources (e.g., databases, registers) ¡ — ·· — ·
Restrictions (e.g., years, publication status, language) ¡ — ¡ · ¡ ·
Selection
Inclusion/exclusion criteria (e.g., defining population,
intervention, outcomes, and study design) ¡¡ ··¡ ·
Validity assessment
Criteria and process used (e.g., masked conditions, quality
assessment, and their findings) — — ·· — ·
Data abstraction
Process used (e.g., completed independently or in duplicate) — — ··¡ ·
Study characteristics
Type of study design ·· · · ——
Participants’ characteristics — ·· · ——
Details of intervention — ·· · ——
Outcome definitions — ·· · ¡ —
How clinical heterogeneity assessed — — — · ——
Quantitative data synthesis
Measures of effect (e.g., relative risk, hazard ratio) · · ····
Method of combining results (e.g., statistical testing, CIs) · · ····
Handling of missing data — — — ···
How statistical heterogeneity was assessed — ·· · ——
Rationale for any a priori sub-group and sensitivity analyses — — ·· — ·
Assessment of publication bias — — — · ——
RESULTS
Trial flow
Provide meta-analysis profile summarizing trial flow — — ————
Study characteristics
Present descriptive data for each trial (e.g., age, sample size,
intervention, dose, duration, follow-up period) · — ····
Quantitative data synthesis
Report agreement on selection and validity assessment — — ·· — ·
Present summary results (for each treatment group in trial
and each outcome) · · ··· —
Present data needed to calculate effect sizes and CIs in ITT
analyses (e.g., 2×2 tables of counts, means,
proportions, SDs) ·· · · ——
DISCUSSION
Summarize key findings · · ····
Discuss clinical inferences based on internal and external
validity · ¡ ····
Interpret results in light of the totality of evidence · — ¡¡··
Describe potential biases in the review process
(e.g., publication bias) · — ¡¡¡¡
Suggest future research agenda — — ·· — ¡
IPD = individual patient data; PCTCG = Prostate Cancer Trialists’ Collaborative Group; CIs = confidence intervals; ITT = intent-to-treat; SDs =
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APPENDIX B Literature search strategy
MEDLINE EMBASE
1. practice guidelines/ 1. exp randomized controlled trial/
2. practice guideline.pt. 2. exp controlled study/
3. practice guideline?.ti,tw. 3. Major Clinical Study/
4. meta-analysis/ 4. Clinical trial/
5. metaanal:.ti,tw. 5. or/1–4
6. meta-anal:.ti,tw. 6. random:.ti,tw.
7. metanal:.ti,tw. 7. 5 and 6
8. systematic review?.ti,tw. 8. exp meta-analysis/
9. systematic overview?.ti,tw. 9. meta-analysis.ti,tw.
10. quantitative overview?.ti,tw. 10. (meta-anal: or meta anal:).ti,tw.
11. quantitative synthes#s.ti,tw. 11. (quantitative overview: or quantitative synth:).ti,tw.
12. randomized controlled trials/ 12. (systematic review: or systematic overview:).ti,tw.
13. randomized controlled trial.pt. 13. exp practice guideline/
14. random allocation/ 14. practice guideline.ti,tw.
15. double-blind method/ 15. or/8–14
16. single-blind method/ 16. 7 or 15
17. random:.ti,tw. 17. exp prostate tumor/
18. controlled clinical trial.pt. 18. exp prostate cancer/
19. clinical trial, phase iii.pt. 19. (prostat: cancer or prostat: carcinoma: or prostat: tumo?r: or prostat: malignan:).ti,tw.
20. or/1–19 20. *prostate tumor/dt
21. leuprolide.ti,tw. 21. *prostate cancer/dt
22. lupron.ti,tw. 22. or/17–21
23. goserelin.ti,tw. 23. total androgen blockade.ti,tw.
24. zoladex.ti,tw. 24. maximal androgen blockade.ti,tw.
25. buserelin.ti,tw. 25. androgen ablation.ti,tw.
26. suprefact.ti,tw. 26. flutamide.ti,tw.
27. flutamide.ti,tw. 27. eulexin.ti,tw.
28. eulexin.ti,tw. 28. nilutamide.ti,tw.
29. nilutamide.ti,tw. 29. anandron.ti,tw.
30. anandron.ti,tw. 30. nilandron.ti,tw.
31. nilandron.ti,tw. 31. bicalutamide.ti,tw.
32. bicalutamide.ti,tw. 32. casodex.ti,tw.
33. casodex.ti,tw. 33. cyproterone acetate.ti,tw.
34. cyproterone acetate.ti,tw. 34. androcur.ti,tw.
35. androcur.ti,tw. 35. diethylstilbestrol.ti,tw.
36. diethylstilbestrol.ti,tw. 36. des.ti,tw.
37. des.ti,tw. 37. exp gonadorelin/
38. total androgen blockade.ti,tw. 38. exp androgen antagonists/
39. maximal androgen blockade.ti,tw. 39. exp diethylstilbestrol/
40. combined androgen blockade.ti,tw. 40. or/23–39
41. androgen ablation.ti,tw. 41. exp castration/
42. exp gonadorelin/ 42. castration.ti,tw.
43. exp androgen antagonists/ 43. orchidectomy.ti,tw.
44. exp diethylstilbestrol/ 44. orchiectomy.ti,tw.
45. or/21–44 45. monotherapy.ti,tw.
46. exp castration/ 46. leuprolide.ti,tw.
47. castration.ti,tw. 47. lupron.ti,tw.
48. orchidectomy.ti,tw. 48. goserelin.ti,tw.
49. orchiectomy.ti,tw. 49. zoladex.ti,tw.
50. monotherapy.ti,tw. 50. buserelin.ti,tw.
51. or/46–50 51. suprefact.ti,tw.
52. prostatic neoplasms/ 52. or/41–51
53. prostat: cancer.ti,tw. 53. 22 and 40 and 52
54. *prostatic neoplasms/dt 54. 53 and 16
55. or/52–54
56. 45 and 51 and 55
57. 56 and 20